These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 35001700)

  • 1. Surveillance, Self-Governance, and Mortality: The Impact of Prescription Drug Monitoring Programs on U.S. Overdose Mortality, 2000-2016.
    Vuolo M; Frizzell LC; Kelly BC
    J Health Soc Behav; 2022 Sep; 63(3):337-356. PubMed ID: 35001700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescription drug monitoring programs and drug overdose deaths involving benzodiazepines and prescription opioids.
    Liang D; Shi Y
    Drug Alcohol Rev; 2019 Jul; 38(5):494-502. PubMed ID: 31317593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
    Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
    MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A typology of prescription drug monitoring programs: a latent transition analysis of the evolution of programs from 1999 to 2016.
    Smith N; Martins SS; Kim J; Rivera-Aguirre A; Fink DS; Castillo-Carniglia A; Henry SG; Mooney SJ; Marshall BDL; Davis C; Cerdá M
    Addiction; 2019 Feb; 114(2):248-258. PubMed ID: 30207015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of mandatory prescription drug monitoring program (PDMP) use laws on prescriber registration and use and on risky prescribing.
    Strickler GK; Zhang K; Halpin JF; Bohnert ASB; Baldwin GT; Kreiner PW
    Drug Alcohol Depend; 2019 Jun; 199():1-9. PubMed ID: 30954863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. State prescription drug monitoring programs and fatal drug overdoses.
    Nam YH; Shea DG; Shi Y; Moran JR
    Am J Manag Care; 2017 May; 23(5):297-303. PubMed ID: 28738683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescription drug monitoring programs operational characteristics and fatal heroin poisoning.
    Martins SS; Ponicki W; Smith N; Rivera-Aguirre A; Davis CS; Fink DS; Castillo-Carniglia A; Henry SG; Marshall BDL; Gruenewald P; Cerdá M
    Int J Drug Policy; 2019 Dec; 74():174-180. PubMed ID: 31627159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of New York prescription drug monitoring program, I-STOP, on statewide overdose morbidity.
    Brown R; Riley MR; Ulrich L; Kraly EP; Jenkins P; Krupa NL; Gadomski A
    Drug Alcohol Depend; 2017 Sep; 178():348-354. PubMed ID: 28692945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mandatory Review of Prescription Drug Monitoring Program Before Issuance of a Controlled Substance Results in Overall Reduction of Prescriptions Including Opioids and Benzodiazepines.
    Manders L; Abd-Elsayed A
    Pain Physician; 2020 Jun; 23(3):299-304. PubMed ID: 32517396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mandatory use of prescription drug monitoring program and benzodiazepine prescribing among U.S. Medicaid enrollees.
    Liang D; Guo H; Shi Y
    Subst Abus; 2021; 42(3):294-301. PubMed ID: 31697195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Prescription Drug Monitoring Programs With Opioid Prescribing and Overdose in Adolescents and Young Adults.
    Toce MS; Michelson KA; Hudgins JD; Hadland SE; Olson KL; Monuteaux MC; Bourgeois FT
    Ann Emerg Med; 2023 Apr; 81(4):429-437. PubMed ID: 36669914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescription drug monitoring program design and function: A qualitative analysis.
    Rutkow L; Smith KC; Lai AY; Vernick JS; Davis CS; Alexander GC
    Drug Alcohol Depend; 2017 Nov; 180():395-400. PubMed ID: 28978492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impacts of prescription drug monitoring program policy changes and county opioid safety coalitions on prescribing and overdose outcomes in California, 2015-2018.
    Henry SG; Shev AB; Crow D; Stewart SL; Wintemute GJ; Fenlon C; Wirtz SJ
    Prev Med; 2021 Dec; 153():106861. PubMed ID: 34687731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring Relationships Between Proactive Reporting State-level Prescription Drug Monitoring Programs and County-level Fatal Prescription Opioid Overdoses.
    Cerdá M; Ponicki WR; Smith N; Rivera-Aguirre A; Davis CS; Marshall BDL; Fink DS; Henry SG; Castillo-Carniglia A; Wintemute GJ; Gaidus A; Gruenewald PJ; Martins SS
    Epidemiology; 2020 Jan; 31(1):32-42. PubMed ID: 31596794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of prescription drug monitoring programs (PDMPs) on opioid utilization among Medicare beneficiaries in 10 US States.
    Moyo P; Simoni-Wastila L; Griffin BA; Onukwugha E; Harrington D; Alexander GC; Palumbo F
    Addiction; 2017 Oct; 112(10):1784-1796. PubMed ID: 28498498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Must-access prescription drug monitoring programs and the opioid overdose epidemic: The unintended consequences.
    Kim B
    J Health Econ; 2021 Jan; 75():102408. PubMed ID: 33316762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. State-level prescription drug monitoring program mandates and adolescent injection drug use in the United States, 1995-2017: A difference-in-differences analysis.
    Earlywine JJ; Hadland SE; Raifman J
    PLoS Med; 2020 Sep; 17(9):e1003272. PubMed ID: 32976539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between statewide prescription drug monitoring program (PDMP) requirement and physician patterns of prescribing opioid analgesics for patients with non-cancer chronic pain.
    Lin HC; Wang Z; Boyd C; Simoni-Wastila L; Buu A
    Addict Behav; 2018 Jan; 76():348-354. PubMed ID: 28898808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Prescription Drug Monitoring Programs and Nonfatal and Fatal Drug Overdoses: A Systematic Review.
    Fink DS; Schleimer JP; Sarvet A; Grover KK; Delcher C; Castillo-Carniglia A; Kim JH; Rivera-Aguirre AE; Henry SG; Martins SS; Cerdá M
    Ann Intern Med; 2018 Jun; 168(11):783-790. PubMed ID: 29801093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physicians' Perspectives Regarding Prescription Drug Monitoring Program Use Within the Department of Veterans Affairs: a Multi-State Qualitative Study.
    Radomski TR; Bixler FR; Zickmund SL; Roman KM; Thorpe CT; Hale JA; Sileanu FE; Hausmann LRM; Thorpe JM; Suda KJ; Stroupe KT; Gordon AJ; Good CB; Fine MJ; Gellad WF
    J Gen Intern Med; 2018 Aug; 33(8):1253-1259. PubMed ID: 29520747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.